The Biology of Human Cancer, and the Development of a Rational Basis for Treatment

  • Arthur S. Levine
Part of the Cancer Growth and Progression book series (CAGP, volume 1)

Abstract

Cancer is a very “old” disease, with the earliest recorded descriptions of tumors and their treatment found in Egyptian papyrie dating from 1600 B.C. (125). Nevertheless, little if any insight was brought to bear on the biology of cancer until the 19th century, with Schleiden and Schwann’s discovery of the cellular nature of all organisms (140) and Muller’s formulation of microscopic pathology as the foundation of our understanding of disease (99). Later in the 19th century, Virchow proposed that all cells arise from other cells, and that cancer reflected a constitutional predisposition together with an exciting cause, such as chronic irritation. Virchow also promulgated the notion of metastases (143), although he believed the metastatic process to have a “fluid” rather than a cellular basis. Modern cancer research began with Peyton Rous’ demonstration in 1911 that sarcomas in the Plymouth Rock hen could be transmitted to normal hens by the injection of cell-free filtrates of the original tumor (117), suggesting the existence of identifiable cancer-causing agents.

Keywords

Acute Lymphocytic Leukemia Human Tumor Cell Complementation Group Rous Sarcoma Virus Avian Sarcoma Virus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Adams JM et al: C-Myc oncogene driven by immunoglobulin enhancer induces lymphoid malignancy in trans-genic mice. Nature 318:533–5, 1985PubMedGoogle Scholar
  2. 2.
    Ah FW, Kellems RE, Bertino JR, Schimke RT: Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J Biol Chem 253:1357–70, 1978Google Scholar
  3. 3.
    Ames RN, Durston WE, Yamasaki E et al: Carcinogens are mutagens: A simple test system combining liver homogenates for activation and bacteria for detection. Proc Natl Acad Sci USA 70:2281–5, 1973PubMedGoogle Scholar
  4. 4.
    Arcamone F, Cassinelli G, Fantini G et al: Adriamycin. 14 hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Biochem 11:1101, 1969Google Scholar
  5. 5.
    Ballmer-Hofer K, Benjamin T: Modulation of phosphorylation of plasma membrane proteins in polyma virus infected cells by the HR-T gene of polyoma virus (abstract). J Cell Biochem Suppl 8A:253, 1984Google Scholar
  6. 6.
    Baltimore D: Viral RNA-dependent DNA polymerase. Nature 226:1209–11, 1970PubMedGoogle Scholar
  7. 7.
    Barbacid M: Oncogenes in human cancers and in chemically induced animal tumors. Prog Med Virol 32:86–100, 1985PubMedGoogle Scholar
  8. 8.
    Bartlett GI, Kreider JW, Purnell DM: Immunotherapy of cancer in animals: Models or muddles. J Natl Cancer Inst 56:207–10, 1976PubMedGoogle Scholar
  9. 9.
    Bell E, Marek LF, Levinstone DS et al: Loss of division potential in vitro: Aging or differentiation? Science 202:1158–63, 1978PubMedGoogle Scholar
  10. 10.
    Berenblum I: The cocarcinogenic action of croton resin. Cancer Res 1:44–9, 1941Google Scholar
  11. 11.
    Bishop JM: Cancer genes come of age. Cell 32:1018–20, 1983PubMedGoogle Scholar
  12. 12.
    Bishop JM: Retroviruses and cancer genes. In: Klein G, Weinhouse S (eds) Advances in Cancer Research, vol. 37, New York: Academic Press, pp. 1–32, 1982Google Scholar
  13. 13.
    Bishop JM, Varmus H: Functions and origins of retroviral transforming genes. In: Weiss R, Teich N, Varmus H, Coffin J (eds). RNA Tumor Viruses. New York: Cold Spring Laboratory, pp. 99–1109, 1982Google Scholar
  14. 14.
    Bittner JJ: Some possible effects of nursing on mammary gland tumor incidence in mice. Science 84: 162–3, 1936PubMedGoogle Scholar
  15. 15.
    Boveri T: Zellenstudien VI. Die Entwicklung dispermer Seeigeleier. Ein Beitrag zur Befruchtungslehre und zur Theorie des Kerns. Z Naturwiss 43:1, 1907Google Scholar
  16. 16.
    Bruce WR, Meeker BE, Valeriote FA: Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst 37:233–245, 1966PubMedGoogle Scholar
  17. 17.
    Brugge JS, Erickson RL: Identification of a transformationspecific antigen induced by an avian sarcoma virus. Nature 269:346–8, 1977PubMedGoogle Scholar
  18. 18.
    Burkitt D: A sarcoma involving the jaws in African children. Br J Surg 46: 218–23, 1958PubMedGoogle Scholar
  19. 19.
    Burkitt D, Hutt MSR, Wright DH: The African lymphoma. Preliminary observations on response to therapy. Cancer 18:399–410, 1965PubMedGoogle Scholar
  20. 20.
    Burchenal JH: Adjuvant therapy-theory, practice, and potential. The James Ewing Lecture. Cancer 37: 46–57, 1976PubMedGoogle Scholar
  21. 21.
    Burchenal JH, Murphy MI, Ellison RR et al: Clinical evaluation of a new antimetabolite in the treatment of leukemia and allied diseases. Blood 8:964–999, 1953Google Scholar
  22. 22.
    Burgert EO, Glidewell O: Dactinomycin in Wilms’ tumor. JAMA 199:464–8, 1967PubMedGoogle Scholar
  23. 23.
    Canellos GP, DeVita VT Jr, Arseneau JC et al: Second malignancies complicating Hodgkin’s disease in remission. Lancet 1:947, 1975PubMedGoogle Scholar
  24. 24.
    Chermann JC, Barre-Sinoussi F, Montagnier L: A new human retrovirus associated with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex. Prog Clin Biol Res 182:329–42, 1985PubMedGoogle Scholar
  25. 25.
    Coccia P, Sather H, Nesbit M et al: Inter-relationship of initial WBC, age and sex in predicting prognosis in childhood acute lymphoblastic leukemia. Am Soc Hematology Meeting (abstract), 1976Google Scholar
  26. 26.
    Cohen SN, Chang ACY, Boyer HW et al: Construction of biologically functional plasmids in vitro. Proc Natl Acad Sci USA 70:3240–4, 1973PubMedGoogle Scholar
  27. 27.
    Cooper GM, Lane M-A, Krontiris TG, Goubin G: Analysis of cellular transforming genes by transfection. In: Klein G (ed) Advances in Viral Oncology, Vol. 1, New York: Raven Press, pp. 243–59, 1982Google Scholar
  28. 28.
    Danna KJ, Nathans D: Bidirectional replication of simian virus 40 DNA. Proc Natl Acad Sci USA 69:3097–3100, 1972PubMedGoogle Scholar
  29. 29.
    D’Angio GJ, Evans AE, Breslow N et al: The treatment of Wilms’ tumor — results of the National Wilms’ Tumor Study. Cancer 38:633–46, 1976PubMedGoogle Scholar
  30. 30.
    Davis WH: The relation of the foreign population to the mortality rates of Boston. Bull Am Acad Med 14:19–54, 1913Google Scholar
  31. 31.
    DeVita VT, Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, PA: JB Lippincott Company, 1986Google Scholar
  32. 32.
    DeVita VT, Jr, Serpick A, Carbon PP: Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 73:881–95, 1970PubMedGoogle Scholar
  33. 33.
    Djerassi I, Boyer G, Treat C et al: Management of childhood lymphosarcoma and reticulum cell sarcoma with high dose methotrexate and vitrovorum factor. Proc Am Assoc Cancer Res 9:18 (abstract), 1968Google Scholar
  34. 34.
    Doll R, Hill AB: Smoking and cancer of the lung. Br Med J 2:739–48, 1950PubMedGoogle Scholar
  35. 35.
    Donner P, Greiser-Wilke R, Moelling K: Nuclear localization and DNA binding of the transforming gene product of avian myelocytomatosis virus. Nature 296:262–6, 1982PubMedGoogle Scholar
  36. 36.
    Downward J, Yarden Y, Mayes E et al: Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307:521–7, 1984PubMedGoogle Scholar
  37. 37.
    Dubost M, Gauter P, Maral R et al: Un nouvel antibiotique a proprietes antitumorales. CR Acad Sci Paris 257:1813–20, 1963Google Scholar
  38. 38.
    Duesberg PH: Retroviral transforming genes in normal cells? Nature 304:219–26, 1983PubMedGoogle Scholar
  39. 39.
    Dulbecco R: Cell transformation by viruses. Science 166:962–8, 1969PubMedGoogle Scholar
  40. 40.
    Einhorn LH, Furnas BF, Powell N: Combination chemotherapy of disseminated testicular carcinoma with cis-platinum diammine dichloride (CPDD), vinblastine (VLB) and bleomycin (BLEO) Prod Am Soc Clin Oncol 17:240, 1976Google Scholar
  41. 41.
    Ellison RR, Glidewell O: Improved survival in adults with acute myelocytic leukemia. Proc Am Assoc Cancer Res 20:161, 1979Google Scholar
  42. 42.
    Ellison RR, Holland JF, Weil M et al: Arabinosyl cytosine. A useful agent in the treatment of acute leukemia in adults. Blood 32:507–23, 1968PubMedGoogle Scholar
  43. 43.
    Farber S, D’Angio G, Evans A et al: Clinical studies of actinomycin D with special reference to Wilms’ tumor in children. Ann NY Acad Sci 89:421–5, 1960PubMedGoogle Scholar
  44. 44.
    Farber S, Diamond LK, Mercer RD et al: Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroylglutamic acid (Aminopterin). N Eng J Med 238:787, 1948Google Scholar
  45. 45.
    Farber S: The effect of ACTH in acute leukemia in childhood. In: Mote JR (ed) Proc of the First Clinical ACTH Conference New York: Blakiston p. 328, 1950Google Scholar
  46. 46.
    Foley EJ: Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res 13:835, 1953PubMedGoogle Scholar
  47. 47.
    Frei E, III, Freireich ET, Gehan E et al: Studies of sequential and combination antimetabolite therapy in acute leukemia, 6-mercaptopurine and methotrexate. Blood 18:431–545, 1961Google Scholar
  48. 48.
    Freireich EJ, Karon M, Frei E, III: Quadruple combination therapy (VAMP) for acute lymphocytic leukemia of childhood. Proc Am Assoc Cancer Res 5:20, 1964Google Scholar
  49. 49.
    Forth J, Kahn MC: The transmission of leukemia of mice with a single cell. Am J Cancer 31:276–82, 1937Google Scholar
  50. 50.
    Galen T: On Anatomical Procedures, the Later Books (Duckworth, WLH, trans). Cambridge: Cambridge University Press. 1962Google Scholar
  51. 51.
    Gilman A: The initial clinical trial of nitrogen mustard. Am J Surg 105:574–5, 1963PubMedGoogle Scholar
  52. 52.
    Goldie JH, Coldman AJ: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727–33, 1979PubMedGoogle Scholar
  53. 53.
    Gottdiener JS, Mathisen DJ, Borer JS et al: Doxorubin cardiotoxicity: Assessment of the late left ventricular dysfunction by radionuclide cineangiography. Ann Intern Med 94:430–5, 1951Google Scholar
  54. 54.
    Graham FL, Abrahams PJ, Mulder C et al: Studies on in vitro transformation by DNA and DNA fragments of human adenoviruses and Simian virus 40. Cold Spring Harbor Symp Quant Biol 39:637–50, 1974Google Scholar
  55. 55.
    Gray LH: Oxygenation in radiotherapy. 1. Radiobiological considerations. Br J Radiol 30:403–6, 1957PubMedGoogle Scholar
  56. 56.
    Groffen J, Heisterkamp N, Stephenson JR et al: C-sis is translocated from chromosome 22 to chromosome 9 in chronic myelocytic leukemia. J Exp Med 158:9–15, 1983PubMedGoogle Scholar
  57. 57.
    Groopman JE, Hartzband PI, Shulman L et al: Antibody seronegative human T-lymphotropic virus type III (HTLV-III)-infected patients with acquired immunodeficiency syndrome or related disorders. Blood 66(3):742–4, 1985PubMedGoogle Scholar
  58. 58.
    Grodzicker T, Hopkins N: Origins of contemporary DNA tumor virus research. In: Tooze, J (ed). “DNA Tumor Viruses.” New York: Cold Spring Laboratory, pp. 1–61, 1981Google Scholar
  59. 59.
    Gros P, Croop J, Roninson I et al: Isolation and characterization of DNA sequences amplified in multidrug-resistant hamster cells. Proc Natl Acad Sci USA 83:337–41, 1986PubMedGoogle Scholar
  60. 60.
    Gross L: Intradermal immunization of C311 mice against a sarcoma that originated in an animal of the same line. Cancer Res 3:326–33, 1943Google Scholar
  61. 61.
    Haddow A, Sexton WA: Influence of carbamic esters (urethanes) on experimental animal tumors. Nature 157:500–03, 1946PubMedGoogle Scholar
  62. 62.
    Haenszel W: Cancer mortality among the foreign-born in the United States. J Natl Cancer Inst 26:37–132, 1961PubMedGoogle Scholar
  63. 63.
    Halsted WS: Surgical Papers. Baltimore: Johns Hopkins, 1924Google Scholar
  64. 64.
    Hayflick L, Moorehead P: The serial cultivation of human diploid cell strains. In: Pollack, R (ed), Readings in Mammalian Cell Culture. New York: Cold Spring Laboratory, pp. 27–64, 1981Google Scholar
  65. 65.
    Hayward WS, Neel B, Astrin S: Activation of a cellular one gene by promoter insertion in ALV-induced lymphoid leukosis. Nature 290:475–80, 1981PubMedGoogle Scholar
  66. 66.
    Hellstrom I, Hellstrom KE, Evans CA et al: Serum mediated protection of neoplastic cells from inhibition by lymphocytes immune to their tumor-specific antigens. Proc Natl Acad Sci USA 62:362–8, 1969PubMedGoogle Scholar
  67. 67.
    Hellstrom L, Hellstrom KF, Sjogren HO et al: Serum factors in tumor-free patients cancelling the blocking of cell-mediated tumour immunity. Int J Cancer 8:185–91. 1971PubMedGoogle Scholar
  68. 68.
    Herberman RB. Natural cell-mediated cytotoxicity in male mice. In: Fogh J; Giovanella BC (eds). The Nude Mouse in Experimental and Clinical Research. New York: Academic Press, pp. 135–66, 1978Google Scholar
  69. 69.
    Herbst AL, Code P, Colton T et al; Age-incidence and risk of diethylstilbestrol-related clear cell adenocarcinoma of the vagina and cervix. Am J Obstet Gynecol 125:43–50. 1977Google Scholar
  70. 70.
    Hertz R, Lewis J, Lipsett MB: Five Years experience with the chemotherapy of metastatic trophoblastic diseases in women. Am J Obstet Gynecol 86:805–14. 1963Google Scholar
  71. 71.
    Hibbs JB, Jr, Lambert LH, Jr, Remington JS: Possible role of macrophage mediated nonspecific cytotoxicityrin tumour resistance. Nature New Biol 235:45–50, 1972Google Scholar
  72. 72.
    Hill JM, Roberts J, Loch E et al: L-asparaginase therapy for leukemia and other malignant neoplasms. JAMA 202:882–8. 1967PubMedGoogle Scholar
  73. 73.
    Hitchings GH, Elion GB: The chemistry and biochemistry of purine analogs. Ann NY Acad Sci 60:195–9, 1954PubMedGoogle Scholar
  74. 74.
    Hoffman-Falk H, Einat P, Shilo B-Z: Drosophila melanogaster DNA clones homologous to vertebrate oncogenes: Evidence for a common ancestor to the sre and abl cellular genes. Cell 32; 589–98, 1983PubMedGoogle Scholar
  75. 75.
    Howard A, Pele SR: Synthesis of deoxyribonucleic acid and nuclear incorporation of S/35 as shown by autoradiographs. In: Wolstenholme GFW (ed). Isotopes in Biochemistry. London: Churchill, pp. 138+, 1951Google Scholar
  76. 76.
    Huebner RJ, Todaro GI: Oncogenes of RNA tumor viruses as determinants of cancer. Proc Natl Acad Sci USA 64:1087–94, 1969PubMedGoogle Scholar
  77. 77.
    Huggins C, Hodges CV: Studies on prostatic cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1:293–7, 1941Google Scholar
  78. 78.
    Hunter T, Sefton BM: The transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc Natl Acad Sci USA 77:1311–15, 1980PubMedGoogle Scholar
  79. 79.
    Kaplan HS: Fundamental mechanisms in combined modality therapy of cancer. Janeway lecture, 1977. Am J Roentgenol 129:383–93, 1977Google Scholar
  80. 80.
    Karon MR, Freireich EJ, Frei F, III: A preliminary report on vincristine sulfate a new agent for the treatment of acute leukemia. Pediatrics 30:791–6, 1962Google Scholar
  81. 81.
    Kirsch IB, Morton C, Korsmeyer S et al: Translocations that highlight chromosomal regions of differentiated activity. J Cell Biochem Suppl 8A:88 (abstract), 1984Google Scholar
  82. 82.
    Klein G: Specific chromosomal translocations and the genesis of B-cell derived tumors in mice and men. Cell 32:311–5. 1983PubMedGoogle Scholar
  83. 83.
    Klein G: Tumor antigens. Ann Rev Microbiol 20:223–52, 1966Google Scholar
  84. 84.
    Kontiris TG: The emerging genetics of human cancer. New Engl J Med 309:404–09, 1983Google Scholar
  85. 85.
    Land H, Parada LF, Weinberg RA: Cellular oncogenes and multistep carcinogenesis. Science 22:771–78, 1983Google Scholar
  86. 86.
    Land H, Parada LF, Weinberg RA: Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304:596–602, 1983Google Scholar
  87. 87.
    Levine AS: Cancer in the Young. Masson Publishing, Inc. USA, 767 pp, 1982Google Scholar
  88. 88.
    Levine AS: Fruit flies, yeasts and one genes: Developmental biology and cancer research come together. Med Ped Oncol 12:357–74, 1984Google Scholar
  89. 89.
    Levine AS: Viruses, immune dysregulation, and oncogenesis: inferences regarding the cause and evolution of AIDS. In: AIDS: The Epidemic of Kaposi’s Sarcoma and Opportunistic Infections. Friedman-Kien, AE; LJ Laubenstein (eds). Masson Publishing, Inc. USA, pp. 7–21, 1984Google Scholar
  90. 90.
    Levine AS, Cook JL, Patch CT et al: Adenovirus 2 early gene expression suppresses the tumorigenicity of hybrids formed between hamster cells transformed by adenovirus 2 and simian virus 40. In: Bishop, JM; Graves, M; Rowley, JD (eds) Genes and Cancer. New York: A.R. Liss, pp. 621–38, 1984Google Scholar
  91. 91.
    Li MC, Hertz R, Spencer DH: Effect of methotrexate upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med 93:361–6, 1956PubMedGoogle Scholar
  92. 92.
    Luria SF, Delbruck M: Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28:491–511. 1943PubMedGoogle Scholar
  93. 93.
    Lynch K, Smith W: Pulmonary asbestosis in carcinoma of the lung in asbesto-silicosis. Am J Cancer 24:56–64, 1935Google Scholar
  94. 94.
    Mendelsohn MI: Autoradiographic analysis of cell proliferation in spontaneous breast cancer of c3H mouse III. The growth fraction. J Natl Cancer Inst 28:1015–29, 1962PubMedGoogle Scholar
  95. 95.
    Miller JA: Carcinogenesis by chemicals: An overview GHA Clowes Memorial Lecture. Cancer Res 30:559–76, 1970PubMedGoogle Scholar
  96. 96.
    Miller RW: The discovery of human teratogens, carcinogens and mutagens. Lessons for the future. In: Hollaender A, deSerres RJ (eds) Chemical Mutagens, vol. 5. New York: Plenum, 1978Google Scholar
  97. 97.
    Milstein C, Kohler G: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–7, 1975PubMedGoogle Scholar
  98. 98.
    Mitchison NA, Kinlen IJ: Present concepts in immune surveillance, in; Fougereau, M; Daussel, J (eds) Progress in Immunology 1980. London: Academic Press, pp. 641–50, 1980Google Scholar
  99. 99.
    Muller J: Classics in oncology. CA 21:305–12, 1971Google Scholar
  100. 100.
    Muller R, Slamon DJ, Tremblay JM et al: Differential expression of cellular oncogenes during pre- and postnatal development of the mouse. Nature 299:640–4, 1982PubMedGoogle Scholar
  101. 101.
    Murphree Al, Benedict WF: Retinoblastoma: Clues to human oncogenesis. Science 223:1028–33, 1984PubMedGoogle Scholar
  102. 102.
    Nebert DW: Genetic differences in susceptibility to chemically induced myelotoxicity and leukemia. Environ Health Prospect 39:11–22. 1981Google Scholar
  103. 103.
    Nebert DW, Gonzalez FJ: Cytochrome P-450 gene expression and regulation. Trends in Pharmacol Sci 6:160–4, 1985Google Scholar
  104. 104.
    Newbold R, Overell RW: Fibroblast immortality is a prerequisite for transformation by EJ c-Ha-ras oncogene. Nature 304:648–51, 1983PubMedGoogle Scholar
  105. 105.
    Norton L, Simon R: Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 61:1307–17, 1977PubMedGoogle Scholar
  106. 106.
    Nowell PC, Hungerford DA: A unique chromosome in granulocytic leukemia. Science 132:1492, 1960Google Scholar
  107. 107.
    Penrose LS, Mackenzie HJ, Korn MN: A genetical study of mammary cancer. Br J Cancer 2:168–76, 1948PubMedGoogle Scholar
  108. 108.
    Pincus MR, van Renswoude J, Harford JB et al: Prediction of the three-dimensional structure of the transforming region of the human bladder oncogene product and its normal cellular homologue. Proc Natl Acad Sci USA 80:5253–5257, 1983PubMedGoogle Scholar
  109. 109.
    Pinkel D: Five-year follow-up of “total therapy” of childhood lymphocytic leukemia. JAMA 216:648–52, 1971PubMedGoogle Scholar
  110. 110.
    Powers S, Kataoka T, Fasano O et al: Genes in S. cerevisiae encoding proteins with domains homologous to the mammalian ras proteins. Cell 36:607–12, 1984PubMedGoogle Scholar
  111. 111.
    Prehn RT: Immunological surveillance: Pro and con. In: Bach, FH; Good, RA (eds) Clinical Immunobiology, vol. 2. New York: Academic Press, pp. 191–203, 1974Google Scholar
  112. 112.
    Reddy EP, Reynolds RK, Santos E, Barbacid M: A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 300:149–52, 1982PubMedGoogle Scholar
  113. 113.
    Regaud C, Coutard H, Hautant A: Contribution au traitement des cancers endolarynges par les rayons. Tenth Internati Congress of Otolaryngology, pp. 19–22, 1922Google Scholar
  114. 114.
    Reimer RR, Hoover R, Fraumeni JF, Jr, Young RC: Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med. 297:177, 1977PubMedGoogle Scholar
  115. 115.
    Rosenberg B, Van Camp I, Krigas T: Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205:698–9, 1965PubMedGoogle Scholar
  116. 116.
    Rosenberg S: Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. JNCI 75(4):595–603, 1985PubMedGoogle Scholar
  117. 117.
    Rous P: Transmission of a malignant new growth by means of a cell-free filtrate. J Am Med Assoc 50:198, 1911Google Scholar
  118. 118.
    Rowe WP: Leukemia virus genomes in the chromosomal DNA of the mouse. In: Harvey Lecture Series 71. New York: Academic Press, pp. 173–92, 1976Google Scholar
  119. 119.
    Ruley HE: Adenovirus early region IA enables viral and cellular transforming genes to transform primary cells in culture. Nature 304:602–6, 1983PubMedGoogle Scholar
  120. 120.
    Salmon SE, Hamburger AW et al: Quantitation of differential sensitivity of human tumor cells to anticancer agents. New Engl J Med 298:1321–7, 1978PubMedGoogle Scholar
  121. 121.
    Schrier PI, Bernards R, Vaessen RTMJ et al: Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells. Nature 305:771–84, 1983PubMedGoogle Scholar
  122. 122.
    Schultz MD: The supervoltage story. Janeway lecture, 1974. Am J Roentgenol 124:541–59, 1975Google Scholar
  123. 123.
    Selawry OS, Frei E, III: Prolongation of remission in acute lymphocytic leukemia by alteration in dose, schedule and route of administration of methotrexate. Clin Res 12:231 (abstract), 1964Google Scholar
  124. 124.
    Sharp PA: Molecular biology of viral oncogenes. Cold Spring Harb Symp Quant Biol 44:1305–22, 1980PubMedGoogle Scholar
  125. 125.
    Shimkin MB: Contrary to Nature. DHEW Publication No. NIII 76–720. Washington, DC: Government Printing Office, 1977Google Scholar
  126. 126.
    Shope RF: Infectious papillomatosis of rabbits. J Exp Med 58:607–24, 1933PubMedGoogle Scholar
  127. 127.
    Simone JV, Verzosa MS et al: Initial features and prognosis in 363 children with acute lymphocytic leukemia. Cancer 36:2099, 1975PubMedGoogle Scholar
  128. 128.
    Skipper HE: Reasons for success and failure in treatment of murine leukemia with the drugs now employed in treating human leukemias. Cancer Chemotherapy (vol. 1). Ann Arbor, Michigan: University Microfilms Internati, 1978Google Scholar
  129. 129.
    Slamon DJ, deKernion JB, Verma IM, Cline M J: Expression of cellular oncogenes in human malignancies. Science 224:256–62, 1984PubMedGoogle Scholar
  130. 130.
    Smith RL: Recorded and expected mortality among the Japanese of the United States and Hawaii, with special reference to cancer. J Natl Cancer Inst 17:459–73, 1956PubMedGoogle Scholar
  131. 131.
    Sorge LK, Levy BT, Maness PF: pp60/c-src is developmentally regulated in the neural retina. Cell 36:249–57, 1984PubMedGoogle Scholar
  132. 132.
    Stewart TA, Pattengale PK, Leder P: Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 38(3):627–37, 1984PubMedGoogle Scholar
  133. 133.
    Stocks P, Korn MN: A cooperative study of the habits, home life, dietary and family histories of 450 cancer patients and of an equal number of control patients. Ann Eugen (Lond) 5:237–80, 1933Google Scholar
  134. 134.
    Storb R, Weiden PL, Sullivan KM et al: Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304:1529–33, 1981PubMedGoogle Scholar
  135. 135.
    Tan C, Tasaka H, DiMarco A: Clinical studies of daunomycin. Proc Am Assoc Cancer Res 6:64 (abstract), 1965Google Scholar
  136. 136.
    Taub R, Moulding C, Battey J et al: Activation and somatic mutation of the translocated c-myc in Burkitt lymphoma cells. Cell 36:339–48, 1984PubMedGoogle Scholar
  137. 137.
    Temin HM, Mizutani S: RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature 226:1211–13, 1970PubMedGoogle Scholar
  138. 138.
    Terman DS, Young JB, Shearer WT et al: Preliminary observations of the effects on breast adenocarcinoma of plasma perfused over immobilized protein A. N Engl J Med 305:1195–99, 1981PubMedGoogle Scholar
  139. 139.
    Thomas L: The lives of a cell. New York: Viking, 1974Google Scholar
  140. 140.
    Triolo VA: Nineteenth century foundations of cancer research: Advances in tumor pathology, nomenclature, and theories of oncogenesis. Cancer Res 25:75–106, 1965PubMedGoogle Scholar
  141. 141.
    Varmus HE: Form and function of retroviral proviruses. Science 216:812, 1982PubMedGoogle Scholar
  142. 142.
    Waterfield MD, Scarce FT, Whittle N et al: Platelet-derived growth factor is structurally related to the putative transforming protein P28/sis of simian sarcoma virus. Nature 304:35–9, 1983PubMedGoogle Scholar
  143. 143.
    Wilder RJ: The historical development of the concept of metastasis. J Mt Sinai Hosp 23:729–34, 1956Google Scholar
  144. 144.
    Wong-Staal F, Ratner L, Shaw G et al: Molecular biology of human T-lymphotropic retroviruses. Cancer Res 45(9 Suppl):4539s–44s, 1985PubMedGoogle Scholar
  145. 145.
    Yunis JJ: The chromosomal basis of human neoplasia. Science 221:227–365, 1983PubMedGoogle Scholar
  146. 146.
    Zeigler JL, Magrath IT, Olweny CLM: Long survival of Burkitt’s Lymphoma in Uganda. Proc Am Soc Clin Oncol 20:430 (abstract), 1979Google Scholar
  147. 147.
    Zeller, P, Gutmann II., Hegedus B et al: Methylhydrazine derivatives, a new class of cytotoxic agents. Experientia 19:129, 1963PubMedGoogle Scholar
  148. 148.
    Zubrod CG, Schepartz S, Leiter J et al: The chemotherapy program of the National Cancer Institute. History, analysis and plans. Cancer Chemother Rep 50:349–540, 1966Google Scholar

Copyright information

© Kluwer Academic Publishers 1989

Authors and Affiliations

  • Arthur S. Levine

There are no affiliations available

Personalised recommendations